A batch of drug discontinuation recalls involve multiple preparations such as Shuanghuanglian and Omeprazole

Drug supervisors issued documents in many places to stop selling and recall a batch of drugs, involving multiple preparations such as Shuanghuanglian and Omeprazole

Drug Administration issued a document to stop sales and recall two batches of Shuanghuanglian injection

On August 20, the Gansu Provincial Drug Administration issued a notice requesting that the sale and use of two batches of Shuanghuanglian injection produced by Henan Fusen Pharmaceutical Co.

The notice mentioned that the results of Shuanghuanglian injection (batch numbers: 2009023 and 2010131, respectively) produced by Henan Fusen Pharmaceutical Co.

The notification requires that the relevant regulatory authorities quickly organize forces to notify the drug dealers and users in the jurisdiction to immediately stop selling and use the two batches of Shuanghuanglian injection, supervise and guide the drug dealers and users to remove the shelf and seal them, and cooperate with Henan Fusen Pharmaceutical Co.

Distributed documents in many places, recalling a batch of commonly used drugs withdrawn from sale

The author found out that in addition to Gansu, Anhui, Sichuan and other places have recently issued similar notices requiring the suspension of sales and recall of a batch of drugs, involving mesalazine enteric-coated tablets and omeprazole enteric-coated capsules

A few days ago, the Sichuan Provincial Food and Drug Administration issued a notice stating that the three batches of drugs produced by three drug manufacturers including Shanxi Jinhuahuixing Pharmaceutical Co.

Among these unqualified drugs, one is a preparation, which is omeprazole enteric-coated capsules; the other two are traditional Chinese medicine pieces, which are longan meat and fuling skin

For the above-mentioned unqualified drugs, the Sichuan Provincial Food and Drug Administration has required relevant enterprises and units to take risk control measures such as suspension of sales and use, recalls, etc.

At the same time, the relevant drug supervision and administration departments organized investigations into the illegal activities of the above-mentioned enterprises and units in the production and sale of counterfeit and inferior drugs in accordance with the "Pharmaceutical Administration Law of the People's Republic of China", and made the investigation results public in accordance with regulations

A week ago, the Anhui Provincial Food and Drug Administration issued an announcement stating that, according to the Anhui Provincial Drug Sampling Inspection Plan, all levels of the province's drug regulatory authorities and drug inspection agencies have conducted random inspections on the drug quality of drug production, business and user units in the administrative region

According to the announcement, the current sampling information involved a total of 392 sampling units and 1,322 batches of products from 430 pharmaceutical manufacturers.

Among the five batches of non-compliant products, four medicines are involved, three of which are Chinese medicinal materials and their decoctions, namely Digu Bark, Gallus gallus, and Apocynum venetum; the other is mesalazine enteric-coated tablets

In addition, the Anhui Provincial Food and Drug Administration reminds residents that when purchasing drugs, please go to the pharmacy that holds the "Drug Business License" to purchase; when purchasing drugs, please obtain and keep a valid receipt, and carefully check the general drug label on the drug packaging box.